Status:
UNKNOWN
RGD PET/MRI in Sporadic Vestibular Schwannoma
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Acoustic Neuroma
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E\[c(RGDyK)\]2 in patients with spor...
Detailed Description
The radioligand 68Ga-NODAGA- E\[c(RGDyK)\]2 targets the Arg-Gly-Asp (RGD) sequence known to bind with the αvβ3 integrin that is expressed on the surface of angiogenic blood vessels or tumor cells. The...
Eligibility Criteria
Inclusion
- Patients \> 18 years with MRI verified sporadic vestibular schwannomas
- Patients \> 18 år whom max has been in watchful waiting regime in 12 months and/or max. received 1 follow-up MRI scan.
- Must be able to read and understand the patient information in Danish and to give informed consent
Exclusion
- Pregnancy
- Breast-feeding
- Weight more than the maximum weight limit for the PET/MR bed of the scanner (140 kg)
- History of allergic reaction attributable to compounds of similar chemical or biologic composition to 68Ga-NODAGA-E\[c(RGDyK)\]2
- Recent systemic treatment with steroids
- Hormone treatment incl. birth control pills.
- Claustrofobia
- Non-MRI compatible implants.
Key Trial Info
Start Date :
January 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 2 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03393689
Start Date
January 2 2018
End Date
January 2 2021
Last Update
January 10 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Otolaryngology, Head and Neck Surgery & Audiology, Rigshospitalet
Copenhagen, Denmark, 2100